SCHEMBL4639533

SCHEMBL4639533

Cc1ccc(S(=O)(=O)c2ccc(F)cc2)cc1S(=O)(=O)NCCc1ccc2c(c1)OCO2

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SFRP1 Q8N474 1/20 0.57
▸ POLB P06746 2/20 0.55
▸ ATM Q13315 1/20 0.55
▸ PDE4B Q07343 1/20 0.53
▸ PDE4C Q08493 1/20 0.53
▸ PDE4D Q08499 1/20 0.53
▸ ALDH1A1 P00352 6/20 0.50
▸ HSD17B10 Q99714 1/20 0.48
▸ PKM P14618 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638952 0.92 POLB (0.63) SFRP1POLBATMPDE4BPDE4C
SCHEMBL4637925 0.91 SFRP1 (0.71) SFRP1POLBATMPDE4BPDE4C
SCHEMBL4637667 0.90 SFRP1 (0.57) SFRP1POLBATMPDE4BPDE4C
SCHEMBL28497471 0.86 ALDH1A1 (0.59) POLBALDH1A1HSD17B10PKMSMN1; SMN2
SCHEMBL4618887 0.86 SFRP1 (0.75) SFRP1POLBALDH1A1PKMSMN1; SMN2
SCHEMBL4617746 0.83 SFRP1 (0.70) SFRP1POLBALDH1A1PKMMAPT
SCHEMBL4619649 0.83 SFRP1 (0.70) SFRP1POLBALDH1A1PKMMAPT
SCHEMBL4617285 0.82 SFRP1 (0.84) SFRP1POLBALDH1A1PKMKMT2A
SCHEMBL4615867 0.81 SFRP1 (0.61) SFRP1POLBALDH1A1PKMMAPT
SCHEMBL4616020 0.81 SFRP1 (0.67) SFRP1POLBALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 — — EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 — — US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 — — WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 — — EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 — — US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 SFRP1 1/4885POLB 4876/4885ATM 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback